Julius Timbol, MS

Data Analyst
Kaiser Permanente Vaccine Study Center
Oakland, CA, United States

Disclosure information not submitted.

Presentation(s):

• 564 - Nirsevimab effectiveness in infants against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) and related healthcare utilization

  Wednesday, October 22, 2025
  11:18 AM - 11:30 AM US ET